IL160148A0 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor - Google Patents
Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumorInfo
- Publication number
- IL160148A0 IL160148A0 IL16014802A IL16014802A IL160148A0 IL 160148 A0 IL160148 A0 IL 160148A0 IL 16014802 A IL16014802 A IL 16014802A IL 16014802 A IL16014802 A IL 16014802A IL 160148 A0 IL160148 A0 IL 160148A0
- Authority
- IL
- Israel
- Prior art keywords
- metastasis
- recurrence
- inhibiting
- preventing
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001249717 | 2001-08-21 | ||
| PCT/JP2002/008309 WO2003015826A1 (en) | 2001-08-21 | 2002-08-16 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastsis or preventing the recurrence of maligant tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL160148A0 true IL160148A0 (en) | 2004-07-25 |
Family
ID=19078678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16014802A IL160148A0 (en) | 2001-08-21 | 2002-08-16 | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1418947A1 (en) |
| KR (1) | KR20040027972A (en) |
| CN (1) | CN100372570C (en) |
| AR (1) | AR035137A1 (en) |
| AU (1) | AU2002328093B2 (en) |
| BR (1) | BR0212036A (en) |
| CA (1) | CA2457056C (en) |
| HU (1) | HUP0401351A3 (en) |
| IL (1) | IL160148A0 (en) |
| MX (1) | MXPA04001599A (en) |
| NO (1) | NO20041194L (en) |
| NZ (1) | NZ530947A (en) |
| PL (1) | PL368319A1 (en) |
| RU (1) | RU2275913C2 (en) |
| TW (1) | TWI313609B (en) |
| UA (1) | UA75450C2 (en) |
| WO (1) | WO2003015826A1 (en) |
| ZA (1) | ZA200400917B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306314A (en) * | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| FR2914305B1 (en) * | 2007-03-29 | 2009-07-03 | Proteins & Peptides Man | DEXTRAN FUNCTIONALIZED BY HYDROPHOBIC AMINO ACIDS |
| CN107988072B (en) | 2008-07-16 | 2022-11-29 | 儿童医疗中心有限公司 | Organ mimic device with microchannels and methods of use and manufacture thereof |
| SG195252A1 (en) * | 2011-06-02 | 2013-12-30 | Harvard College | Methods and uses for ex vivo tissue culture systems |
| PL221351B1 (en) | 2012-03-14 | 2016-03-31 | Politechnika Warszawska | Method for obtaining polysaccharide nanoparticles |
| HUE039000T2 (en) * | 2012-10-11 | 2018-12-28 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate |
| EP2910573B1 (en) * | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
| DK3466976T3 (en) | 2014-01-31 | 2021-12-13 | Daiichi Sankyo Co Ltd | ANTI-HER2-ANTIBODY-MEDICINE CONJUGATE |
| KR102045663B1 (en) | 2015-05-04 | 2019-11-15 | 화이자 인코포레이티드 | Group B Streptococcus polysaccharide-protein conjugate, method of producing the conjugate, immunogenic composition comprising the conjugate, and use thereof |
| IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate compisitions and methods for producing same |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| WO2018135501A1 (en) | 2017-01-17 | 2018-07-26 | 第一三共株式会社 | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| TW202330036A (en) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | Manufacturing method of antibody-drug conjugates |
| CA3073924C (en) | 2017-08-31 | 2023-10-17 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| KR102630307B1 (en) | 2017-08-31 | 2024-01-29 | 다이이찌 산쿄 가부시키가이샤 | Novel method for producing antibody-drug conjugate |
| CA3100608A1 (en) | 2018-05-18 | 2019-11-21 | Daiichi Sankyo Co., Ltd. | Anti-muc1 antibody-drug conjugate |
| CN109481691A (en) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | Gemcitabine-carboxymethyl polysaccharide conjugate, preparation method and its usage |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994019376A1 (en) * | 1993-02-26 | 1994-09-01 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| DE69734709D1 (en) * | 1996-04-15 | 2005-12-29 | Asahi Chemical Ind | MEDICINAL COMPLEXES CONTAINING TAXAN COMPOUNDS OR STEROIDS |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| CN1058038C (en) * | 1996-12-31 | 2000-11-01 | 中国科学院感光化学研究所 | Low contract photo-solidification cladding material, its prepn. method and use |
| CN1250293C (en) * | 1998-05-22 | 2006-04-12 | 第一制药株式会社 | Drug composites |
-
2002
- 2002-08-14 TW TW091118260A patent/TWI313609B/en not_active IP Right Cessation
- 2002-08-15 AR ARP020103077A patent/AR035137A1/en unknown
- 2002-08-16 PL PL02368319A patent/PL368319A1/en not_active Application Discontinuation
- 2002-08-16 IL IL16014802A patent/IL160148A0/en unknown
- 2002-08-16 KR KR10-2004-7002566A patent/KR20040027972A/en not_active Application Discontinuation
- 2002-08-16 HU HU0401351A patent/HUP0401351A3/en unknown
- 2002-08-16 AU AU2002328093A patent/AU2002328093B2/en not_active Ceased
- 2002-08-16 UA UA2004032071A patent/UA75450C2/en unknown
- 2002-08-16 WO PCT/JP2002/008309 patent/WO2003015826A1/en active IP Right Grant
- 2002-08-16 MX MXPA04001599A patent/MXPA04001599A/en unknown
- 2002-08-16 CN CNB028163176A patent/CN100372570C/en not_active Expired - Fee Related
- 2002-08-16 RU RU2004108141/15A patent/RU2275913C2/en not_active IP Right Cessation
- 2002-08-16 BR BR0212036-4A patent/BR0212036A/en not_active IP Right Cessation
- 2002-08-16 NZ NZ530947A patent/NZ530947A/en not_active IP Right Cessation
- 2002-08-16 EP EP02762786A patent/EP1418947A1/en not_active Withdrawn
- 2002-08-16 CA CA002457056A patent/CA2457056C/en not_active Expired - Fee Related
-
2004
- 2004-02-04 ZA ZA200400917A patent/ZA200400917B/en unknown
- 2004-03-19 NO NO20041194A patent/NO20041194L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ530947A (en) | 2006-04-28 |
| KR20040027972A (en) | 2004-04-01 |
| ZA200400917B (en) | 2004-08-25 |
| UA75450C2 (en) | 2006-04-17 |
| HUP0401351A2 (en) | 2004-12-28 |
| CN1545423A (en) | 2004-11-10 |
| HUP0401351A3 (en) | 2011-02-28 |
| CA2457056C (en) | 2008-07-22 |
| RU2275913C2 (en) | 2006-05-10 |
| NO20041194L (en) | 2004-03-19 |
| TWI313609B (en) | 2009-08-21 |
| MXPA04001599A (en) | 2004-07-08 |
| AR035137A1 (en) | 2004-04-14 |
| RU2004108141A (en) | 2005-04-20 |
| CN100372570C (en) | 2008-03-05 |
| CA2457056A1 (en) | 2003-02-27 |
| EP1418947A1 (en) | 2004-05-19 |
| WO2003015826A1 (en) | 2003-02-27 |
| AU2002328093B2 (en) | 2005-05-05 |
| BR0212036A (en) | 2004-08-17 |
| PL368319A1 (en) | 2005-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL160148A0 (en) | Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor | |
| AU3983201A (en) | Compositions and methods for the early diagnosis of ovarian cancer | |
| EP1254267A4 (en) | Compositions and methods for the early diagnosis of ovarian cancer | |
| AU2001231199A1 (en) | Compositions and methods for the early diagnosis of ovarian cancer | |
| AU2002360769A1 (en) | Breast cancer expression profiling | |
| PL354540A1 (en) | Drugs for the treatment of malignant tumours | |
| HUP0400314A3 (en) | Pharmaceutical combinations for the treatment of cancer | |
| AU9684601A (en) | Compositions that inhibit proliferation of cancer cells | |
| EP1476067A4 (en) | Novel compositions and methods for cancer | |
| AU2002246519A8 (en) | Compositions and methods for the therapy and diagnosis of colon cancer | |
| EP1461033A4 (en) | Methods and compositions for ameliorating the undesirable effects of chemotherapy | |
| EP1509539A4 (en) | Novel compositions and methods for cancer | |
| AU2002257033A1 (en) | Agents and methods for the prevention of initial onset and recurrence of existing cancers | |
| AU2002341749A1 (en) | Methods and compositions for inhibiting the proliferation of prostate cancer cells | |
| HUP0402341A3 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
| EP1349485A4 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| GB0110847D0 (en) | Breast cancer detection | |
| AU3483001A (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
| EP1487983A4 (en) | Prevention of recurrence and metastasis of cancer | |
| HUP0300772A3 (en) | Medicament for the immunotherapy of malignant tumours | |
| AU2003270202A8 (en) | Pharmaceutical compositions useful for the treatment of cancers | |
| HUP0302629A3 (en) | Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer | |
| AU2001271284A1 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer | |
| EP1459754A4 (en) | Preventives/remedies for cancer | |
| AU2002332606A8 (en) | Compositions and methods for the therapy and diagnosis of colon cancer |